Meta-analysis of excision repair cross complementary gene 1 (ERCC1) expression and platinum chemosensitivity in patients with ovarian cancer.

Abstract

Ovarian cancer is one of the most common malignant tumors in women. Due to the lack of typical clinical symptoms and ineffective screening methods for early ovarian cancer, 60-70% of patients with ovarian cancer are diagnosed as middle and late stage when they are already suffering abdominal distension, abdominal pain, or pelvic tumor. This study aimed to comprehensively investigate the correlation of excision repair cross complementary gene 1 (ERCC1) expression and the chemosensitivity of ovarian cancer. A meta-analysis was conducted to comprehensively and quantitatively evaluate the relevant research in this area. The literature published in PubMed, Web of Science, CQVIP, China National Knowledge Infrastructure (CNKI), and Wanfang databases from establishment to June 2019 were searched. The evaluation index of chemotherapy sensitivity was clinical effective rate (complete remission plus partial remission). Two researchers independently screened the literature and extracted the data according to the inclusion and exclusion criteria. A total of 7 articles met the inclusion criteria, comprising 402 patients with ovarian cancer. The results showed that there was a significant difference in chemosensitivity between the low ERCC1 expression group and the high ERCC1 expression group (OR =5.19, 95% CI: 3.15-8.54, P<0.01), with the results of the ethnicity subgroup analysis being the same for the Asian and Caucasian populations. The chemosensitivity of ovarian cancer patients with a low expression of ERCC1 is greater than that of patients with high expression.